2024
Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC).
Mercier B, Tripathi N, Govindarajan A, Gebrael G, Narang A, Li X, Castro D, Chehrazi-Raffle A, Dizman N, Ebrahimi H, Chawla N, Hsu J, Bergerot C, Barragan-Carrillo R, Zengin Z, Meza L, Pal S, Agarwal N, Tripathi A. Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC). Journal Of Clinical Oncology 2024, 42: 547-547. DOI: 10.1200/jco.2024.42.4_suppl.547.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaOverall survivalCox proportional hazards multivariate modelPresence of visceral metastasesChi-square test/Fisher's exact testIS groupPractice patternsPredictors of OSKaplan-Meier methodImpact practice patternsLog-rank testMedicare groupPrivate insuranceMulti-institutional studyANOVA/Kruskal-Wallis testVisceral metastasesInsurance payer statusNeoadjuvant chemotherapyNCI-designated comprehensive cancer centerSystemic therapyUrothelial carcinomaMedian ageBaseline characteristicsExact testClinical trial participation
2023
Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).
Leong S, Ali S, Zengin Z, Meza L, Dizman N, Ebrahimi H, Govindarajan A, Castro D, Li X, Kim T, Melamed S, Onyshchenko M, Pal S, Chehrazi-Raffle A. Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi). Journal Of Clinical Oncology 2023, 41: 613-613. DOI: 10.1200/jco.2023.41.6_suppl.613.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaProgression-free survivalSafety-net healthcare systemComprehensive cancer centerShorter progression-free survivalHistory of nephrectomyTertiary care centerOverall survivalLatinx patientsMRCC patientsClinical outcomesCare centerHealthcare systemHope Comprehensive Cancer CenterPoor-risk diseaseTertiary oncology centerImmune checkpoint inhibitorsLos Angeles County DepartmentMedian overall survivalRisk classificationClear cell histologyFirst-line therapyNumber of comorbiditiesKaplan-Meier methodBody mass index
2022
Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo).
Ali S, Leong S, Meza L, Dizman N, Zengin Z, Kim T, Pak Y, Onyshchenko M, Pal S, Chehrazi-Raffle A. Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo). Journal Of Clinical Oncology 2022, 40: 4554-4554. DOI: 10.1200/jco.2022.40.16_suppl.4554.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaIpi/nivoProgression-free survivalTertiary care centerSafety-net healthcare systemCare centerHispanic/LatinxMultivariate Cox proportional hazards regressionShorter progression-free survivalCox proportional hazards regressionSafety-net hospital systemHope Comprehensive Cancer CenterFirst-line ipilimumabFirst-line therapyImmune checkpoint inhibitorsLos Angeles County DepartmentClear cell histologyNumber of comorbiditiesKaplan-Meier methodProportional hazards regressionComprehensive cancer centerHealthcare systemRenal cell carcinomaMultiple social determinantsReal-world analysisImplications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).
Zengin Z, Henderson N, Park J, Ali A, Hwang C, Barata P, Bilen M, Graham L, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A, Dorff T. Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts). Journal Of Clinical Oncology 2022, 40: 138-138. DOI: 10.1200/jco.2022.40.6_suppl.138.Peer-Reviewed Original ResearchAR alterationsAR mutationsGenomic testingAdvanced prostate cancer patientsAndrogen receptor alterationsKaplan-Meier methodLog-rank testProstate cancer patientsAlteration statusMedian TTPPSA declineCastration resistancePSA responseMedian ageAR amplificationDocetaxel exposureReceptor alterationsStratified patientsTestosterone suppressionShorter TTPCancer patientsTreatment outcomesAbirateroneCastration statusDomain mutations